论文部分内容阅读
本文是美国免疫实施咨询委员会1977年公布的白喉、破伤风和百日咳免疫方案的修订本。免疫制品按食品和药物管理局(FDA)规定制造的白喉和破伤风类毒素制品(以下简称白类和破类),其Lf含量各不相同,但未必说明其效力大小。白类的不良反应与剂量和年龄有关,故成人剂量应比儿童小。
This is a revision of the diphtheria, tetanus and pertussis immunization protocols published by the Advisory Committee on Immunization Practice of the United States in 1977. Immunodeficiency Products Diphtheria and tetanus toxoid products (hereinafter referred to as “white and broken”) manufactured according to the Food and Drug Administration (FDA) regulations have different Lf contents but may not necessarily indicate their effectiveness. Adverse reactions to white matter and dose and age-related, adult dose should be smaller than children.